上室性頻拍の世界市場

上室性頻拍の世界市場は2030年までに10億米ドルに達する見込み

2024年に6億4,880万米ドルと推定される上室性頻拍の世界市場は、2030年には10億米ドルに達し、分析期間2024-2030年のCAGRは8.3％で成長すると予測されます。本レポートで分析したセグメントの1つである房室結節再入可能性頻拍は、CAGR 10.8%を記録し、分析期間終了時には4億8,420万米ドルに達すると予測されます。房室回帰性頻拍セグメントの成長率は、分析期間でCAGR 6.2％と推定されます。

米国市場は1億7,680万米ドル、中国はCAGR13.4％で成長予測

米国の上室性頻拍市場は、2024年に1億7,680万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを13.4%として、2030年までに2億3,140万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0%と8.1%と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界の上室性頻拍市場動向と促進要因まとめ

上室性頻拍とは何か、なぜ重要なのか？

上室性頻拍（SVT）とは、心臓の心室の上方で発生する不整脈の一群を指し、心臓機能を著しく混乱させる異常に速い心拍リズムを引き起こします。通常、生命を脅かすことはないが、SVTは患者を苦しめ、衰弱させることがあり、しばしば動悸、めまい、胸痛、疲労などの症状を引き起こします。SVTには房室結節再入可能性頻拍（AVNRT）、房室往復性頻拍（AVRT）、心房頻拍などのサブタイプがあります。これらの不整脈はしばしば電気的リエントリー回路または心臓組織の異常な自動性によって誘発されます。

SVTの臨床的意義は、その高い再発率、予測不可能な発症、特に高齢者や合併症を有する集団においてQOLを損なう可能性にあります。SVTの有病率は世界的に増加しているが、その一因は人口の高齢化、心血管スクリーニングの増加、高血圧や構造的心疾患の罹患率の増加です。急性のエピソードは迷走神経操作やアデノシンなどの薬物でしばしば終息させることができるが、多くの患者は長期的な管理戦略を必要としています。このため、電気生理学、デバイスを用いた介入、薬物療法などの技術革新が強く求められています。

診断と治療プロトコルは技術とともにどのように進化しているか？

SVTの診断と治療は、洗練された診断ツールと介入技術の統合によって大きく進歩しました。ホルターモニター、植え込み型ループレコーダー、携帯型心電図装置などにより、診療中に発見されないような一過性のSVTエピソードを正確に捉えることができるようになりました。非侵襲的なマッピング技術によって、電気生理学者は不整脈発生病巣の位置を驚くほど正確に特定できるようになり、より的を絞った治療の基礎が築かれつつあります。

特にカテーテルアブレーションは、低侵襲でしばしば根治的な解決策を提供することにより、SVT管理に革命をもたらしました。3D電気解剖学的マッピング，心エコー，遠隔磁気ナビゲーションなどの技術革新により，最新のアブレーションシステムは現在，有効性の向上，再発率の低下，安全性の向上を実現しています。薬理学的な面では、催不整脈リスクを減少させた新しい抗不整脈薬が臨床応用されつつあります。遺伝的素因、解剖学的変異、併存疾患を考慮した個別化治療のアプローチも普及しつつあり、SVT治療においてより個別化された標準治療への道が開かれつつあります。

SVT治療薬の世界情勢に影響を与える市場動向とは？

医療のデジタル化、心血管系に対する意識の高まり、高度な心臓治療へのアクセスの拡大が、SVT市場の展望を再構築しています。ウェアラブルECGモニターやモバイルヘルスアプリの普及は、特に外来患者や地方での早期診断に力を与えています。これらのデバイスは、リアルタイムのリズム追跡と循環器専門医とのデータ共有を可能にし、タイムリーな介入を可能にします。クラウドプラットフォームやAIアルゴリズムとの統合も、不整脈検出精度を向上させ、患者固有のデータパターンに基づく実用的な洞察を臨床医に提供しています。

診断と並行して、機器メーカーは、改良されたエネルギー供給システム、リアルタイムのフィードバック機構、AI支援による手技ガイダンスを備えた次世代アブレーション用カテーテルの開発を進めています。また、手技のばらつきや放射線被曝を減らすために、ロボットナビゲーションシステムも検討されています。医薬品の面では、長期使用に耐えうる心拍数およびリズム制御薬の開発に再び焦点が当てられています。規制当局は新規の抗不整脈薬やアブレーション装置の承認経路を合理化し、迅速な臨床導入を促しています。心臓インフラが未発達な地域では、官民パートナーシップや移動式電気生理学的治療装置が、治療格差の是正や治療へのアクセスの向上に役立っています。

上室性頻拍市場の需要増加の要因は？

上室性頻拍市場の成長は、臨床ニーズ、技術革新、ヘルスケアインフラの拡張に関連するいくつかの要因によって牽引されています。心血管疾患の有病率の増加-特に高齢化人口の間で-は、SVTの診断の急増につながっており、より効果的な長期的治療オプションが必要とされています。高血圧、糖尿病、肥満の増加は不整脈感受性の上昇に寄与しており、治療人口をさらに拡大しています。

さらに、電気生理学的技術、特に高周波および冷凍アブレーション・システムの急速な進歩により、インターベンション治療がより身近で成功しやすくなっています。ウェアラブル心臓モニタリング機器の採用は早期診断を促し、手技紹介の増加をもたらしています。先進経済諸国と新興経済諸国の両方で、心臓専門センターの開発と訓練を受けた電気生理学者の確保がアブレーションサービスの拡大を支えています。これと並行して、より安全な抗不整脈薬に焦点を当てた医薬品の研究開発と、心拍数コントロールのための合剤の利用可能性が、薬物療法分野を後押ししています。

心血管系の罹患率減少を目的とした政府の取り組みも、デジタル医療インフラへの投資と並んで重要な役割を果たしています。償還政策の改善とアブレーションが国の保険制度に組み込まれたことで、より多くの患者が決定的な治療を受けるようになっています。最後に、不整脈と最新の心臓治療法の安全性に関する一般市民の意識の高まりは、偏見を減らし、積極的なヘルスケア行動を促しています。

セグメント

タイプ（房室結節再入可能性頻拍、房室回帰性頻拍、心房細動、その他のタイプ）、治療（薬物療法、高周波カテーテルアブレーション、手術）、エンドユーザー（病院・診療所エンドユーザー、外来手術センターエンドユーザー、診断センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Abbott Laboratories
• Amomed Pharma GmbH
• AstraZeneca plc
• Bayer AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Bristol-Myers Squibb Company
• Covis Pharma BV
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals
• Johnson & Johnson Private Limited
• Mayne Pharma Group Limited
• Medtronic plc
• Merck Sharp & Dohme Corp.（MSD）
• Milestone Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• St. Jude Medical（Abbott）
• Teva Pharmaceutical Industries Ltd
• Upsher-Smith Laboratories, LLC

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Supraventricular Tachycardia Market to Reach US$1.0 Billion by 2030

The global market for Supraventricular Tachycardia estimated at US$648.8 Million in the year 2024, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Atrioventricular Nodal Re-entrant Tachycardia, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$484.2 Million by the end of the analysis period. Growth in the Atrioventricular Reciprocating Tachycardia segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$176.8 Million While China is Forecast to Grow at 13.4% CAGR

The Supraventricular Tachycardia market in the U.S. is estimated at US$176.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$231.4 Million by the year 2030 trailing a CAGR of 13.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Supraventricular Tachycardia Market - Key Trends & Drivers Summarized

What Exactly Is Supraventricular Tachycardia and Why Does It Matter?

upraventricular Tachycardia (SVT) refers to a group of arrhythmias that originate above the ventricles in the heart, causing abnormally fast heart rhythms that can significantly disrupt cardiac function. Though not typically life-threatening, SVT can be distressing and debilitating for patients, often causing symptoms such as palpitations, dizziness, chest pain, and fatigue. The condition includes several subtypes such as atrioventricular nodal reentrant tachycardia (AVNRT), atrioventricular reciprocating tachycardia (AVRT), and atrial tachycardia. These arrhythmias are often triggered by electrical re-entry circuits or abnormal automaticity in cardiac tissue.

The clinical significance of SVT lies in its high recurrence rate, unpredictable onset, and the potential to impair quality of life, especially in elderly and comorbid populations. The prevalence of SVT is increasing globally, partly due to aging populations, increased cardiovascular screening, and higher rates of hypertension and structural heart disease. While acute episodes can often be terminated with vagal maneuvers or medications like adenosine, many patients require long-term management strategies. This has created a strong demand for innovations in electrophysiology, device-based interventions, and pharmacological therapy.

How Are Diagnosis and Treatment Protocols Evolving with Technology?

he diagnosis and treatment of SVT have advanced considerably with the integration of sophisticated diagnostic tools and interventional techniques. Holter monitors, implantable loop recorders, and mobile ECG devices have enabled the accurate capture of transient SVT episodes that might otherwise go undetected during clinic visits. Non-invasive mapping technologies are helping electrophysiologists localize arrhythmogenic foci with remarkable precision, laying the foundation for more targeted treatments.

Catheter ablation, in particular, has revolutionized SVT management by offering a minimally invasive, often curative solution. Powered by innovations in 3D electroanatomical mapping, intracardiac echocardiography, and remote magnetic navigation, modern ablation systems now offer improved efficacy, lower recurrence rates, and enhanced safety profiles. On the pharmacological front, newer antiarrhythmic agents with reduced proarrhythmic risk are entering clinical use. Personalized therapy approaches that factor in genetic predisposition, anatomical variations, and comorbid conditions are also gaining traction, paving the way for a more individualized standard of care in SVT treatment.

What Market Trends Are Influencing the Global SVT Therapeutics Landscape?

ealthcare digitization, rising cardiovascular awareness, and growing access to advanced cardiac care are reshaping the SVT market landscape. The proliferation of wearable ECG monitors and mobile health apps is empowering early diagnosis, particularly in outpatient and rural settings. These devices allow real-time rhythm tracking and data sharing with cardiologists, enabling timely interventions. Integration with cloud platforms and AI algorithms is also improving arrhythmia detection accuracy and providing clinicians with actionable insights based on patient-specific data patterns.

Parallel to diagnostics, device manufacturers are developing next-generation ablation catheters with improved energy delivery systems, real-time feedback mechanisms, and AI-assisted procedural guidance. Robotic navigation systems are also being explored to reduce procedural variability and radiation exposure. On the pharmaceutical front, there's renewed focus on developing rate- and rhythm-control medications with better tolerability for long-term use. Regulatory bodies are streamlining approval pathways for novel antiarrhythmic drugs and ablation devices, encouraging rapid clinical adoption. In regions with underdeveloped cardiac infrastructure, public-private partnerships and mobile electrophysiology units are helping close treatment gaps and increase procedural accessibility.

What’s Fueling the Rising Demand in the Supraventricular Tachycardia Market?

he growth in the supraventricular tachycardia market is driven by several factors linked to clinical need, technological innovation, and healthcare infrastructure expansion. The increasing prevalence of cardiovascular diseases-particularly among aging populations-is leading to a surge in SVT diagnoses, necessitating more effective long-term treatment options. Rising rates of hypertension, diabetes, and obesity are contributing to higher arrhythmia susceptibility, further expanding the treatment population.

Moreover, the rapid advancement of electrophysiology technologies-especially radiofrequency and cryoablation systems-is making interventional treatment more accessible and successful. The adoption of wearable cardiac monitoring devices is driving early diagnosis and increasing procedural referrals. Growth in cardiac specialty centers and the availability of trained electrophysiologists in both developed and emerging economies are supporting the expansion of ablation services. In parallel, pharmaceutical R&D focused on safer antiarrhythmic drugs and the availability of fixed-dose combinations for rate control are boosting pharmacotherapy segments.

Government initiatives aimed at reducing cardiovascular morbidity, alongside investments in digital health infrastructure, are also playing a critical role. Reimbursement policy improvements and inclusion of ablation in national insurance programs are encouraging more patients to pursue definitive treatments. Lastly, increasing public awareness about arrhythmias and the safety of modern cardiac procedures is reducing stigma and driving proactive healthcare behavior-all of which are fueling robust growth across the SVT diagnostics and therapeutics market.

SCOPE OF STUDY:

The report analyzes the Supraventricular Tachycardia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation, Other Types); Treatment (Medications, Radiofrequency Catheter Ablation, Surgery); End-Use (Hospital & Clinics End-Use, Ambulatory Surgery Centers End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Amomed Pharma GmbH
• AstraZeneca plc
• Bayer AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Bristol-Myers Squibb Company
• Covis Pharma BV
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals
• Johnson & Johnson Private Limited
• Mayne Pharma Group Limited
• Medtronic plc
• Merck Sharp & Dohme Corp. (MSD)
• Milestone Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• St. Jude Medical (Abbott)
• Teva Pharmaceutical Industries Ltd
• Upsher-Smith Laboratories, LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Supraventricular Tachycardia - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Cardiac Rhythm Disorders Throws the Spotlight on Diagnosis and Management of SVT
  • Advances in Electrophysiology and Mapping Technologies Propel Innovation in SVT Ablation Therapies
  • Growing Use of Wearable ECG Monitors Enhances Early Detection and Patient-Reported SVT Episodes
  • Increase in Minimally Invasive Cardiac Procedures Strengthens Business Case for Catheter Ablation Devices
  • Development of Next-Gen Antiarrhythmic Drugs Expands Pharmacological Management Options
  • Expansion of Ambulatory Heart Monitoring Services Accelerates Market for Holter and Patch Monitors
  • AI-Based Arrhythmia Detection Algorithms Improve SVT Diagnosis and Personalized Treatment
  • Rising Healthcare Infrastructure in Emerging Economies Supports Broader Access to EP Labs and Treatments
  • FDA Approvals and Clinical Guidelines Drive Adoption of SVT Ablation in First-Line Treatment Protocols
  • Patient Awareness Campaigns and Cardiology Screening Programs Spur Earlier Diagnosis and Intervention
  • Integration of SVT Management in Telecardiology Platforms Expands Reach and Efficiency of Care
  • Collaborative Research in Pediatric SVT Opens New Frontiers in Age-Specific Treatment Strategies
  • Growing Cardiologist Workforce and Specialization Boost Market Capacity for EP and SVT Procedures
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Supraventricular Tachycardia Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Supraventricular Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Atrioventricular Nodal Re-entrant Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Atrioventricular Nodal Re-entrant Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Atrioventricular Nodal Re-entrant Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Atrioventricular Reciprocating Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Atrioventricular Reciprocating Tachycardia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Atrioventricular Reciprocating Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Atrial Fibrillation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Atrial Fibrillation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Diagnostic Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Diagnostic Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospital & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Medications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Medications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Radiofrequency Catheter Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Radiofrequency Catheter Ablation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Radiofrequency Catheter Ablation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• JAPAN
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• CHINA
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• EUROPE
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Supraventricular Tachycardia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• FRANCE
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• GERMANY
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Supraventricular Tachycardia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• INDIA
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Supraventricular Tachycardia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Supraventricular Tachycardia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Supraventricular Tachycardia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030
• AFRICA
  • Supraventricular Tachycardia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Supraventricular Tachycardia by Type - Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Supraventricular Tachycardia by Type - Percentage Breakdown of Value Sales for Atrioventricular Nodal Re-entrant Tachycardia, Atrioventricular Reciprocating Tachycardia, Atrial Fibrillation and Other Types for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Supraventricular Tachycardia by End-Use - Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Supraventricular Tachycardia by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers End-Use, Other End-Uses, Hospital & Clinics End-Use and Ambulatory Surgery Centers End-Use for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Supraventricular Tachycardia by Treatment - Medications, Radiofrequency Catheter Ablation and Surgery Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Supraventricular Tachycardia by Treatment - Percentage Breakdown of Value Sales for Medications, Radiofrequency Catheter Ablation and Surgery for the Years 2014, 2025 & 2030

IV. COMPETITION